Earnings Call Summary | PaySign(PAYS.US) Q2 2024 Earnings Conference
Earnings Call Summary | PaySign(PAYS.US) Q2 2024 Earnings Conference
The following is a summary of the Paysign, Inc. (PAYS) Q2 2024 Earnings Call Transcript:
以下是Paysign, Inc. (PAYS) Q2 2024 業績會摘要:
Financial Performance:
金融業績:
Paysign reported a Q2 2024 revenue of $14.3 million, a 29.8% increase year-over-year.
Adjusted EBITDA rose significantly to $2.24 million, reflecting a 96% increase, translating to $0.04 per fully diluted share.
Net income for the quarter was reported at $697,000, or $0.01 per fully diluted share.
Paysign報告Q2 2024營業收入達到1430萬美元,同比增長29.8%。
調整後EBITDA大幅上升至224萬美元,同比增長96%,每股完全稀釋後爲0.04美元。
本季度淨收入爲697,000美元,每股完全稀釋後爲0.01美元。
Business Progress:
業務進展:
The patient affordability segment experienced a 267% increase in revenue, driving significant margin expansion and contributing to 59% of total revenue growth.
Paysign added eight new patient affordability programs in Q2, growing the total to 61 active programs.
Eight new plasma centers were added, reaching a total of 477 centers, with plans to add 5-10 more by year-end.
患者支付能力領域營收增長267%,推動了顯著的利潤率擴張,併爲總營收增長貢獻了59%。
Paysign在Q2新增了8個患者支付能力計劃,總計61個活躍計劃。
新增8個血漿中心,總數達到477個,計劃在年底前再增加5-10個。
Opportunities:
機會:
Paysign's growth is driven by its expanding patient affordability and plasma donor compensation businesses.
The company plans to continue capitalizing on opportunities through robust sales pipelines and strategic expansion into new markets.
Paysign的增長是由擴大患者支付和血漿捐贈者補償業務推動的。
公司計劃通過強大的銷售渠道和戰略性擴展進入新市場,繼續利用機會。
Risks:
風險:
The business depends significantly on the performance of its patient affordability programs and plasma donation centers.
該業務顯著依賴於其患者支付計劃和血漿捐贈中心的表現。
More details: PaySign IR
更多詳情:PaySign投資者關係頁面
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。